CN109689028A - 用于中枢神经系统递送和治疗隐球菌感染的脂质卷包封的抗真菌化合物 - Google Patents

用于中枢神经系统递送和治疗隐球菌感染的脂质卷包封的抗真菌化合物 Download PDF

Info

Publication number
CN109689028A
CN109689028A CN201780056037.8A CN201780056037A CN109689028A CN 109689028 A CN109689028 A CN 109689028A CN 201780056037 A CN201780056037 A CN 201780056037A CN 109689028 A CN109689028 A CN 109689028A
Authority
CN
China
Prior art keywords
lipid
cryptococcus
volume
composition
method described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780056037.8A
Other languages
English (en)
Chinese (zh)
Inventor
R.J.曼尼诺
R.卢
D.F.克林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Matinas Biopharma Nanotechnologies Inc
Original Assignee
Aquarius Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aquarius Biotechnologies Inc filed Critical Aquarius Biotechnologies Inc
Priority to CN202111352284.7A priority Critical patent/CN114053417A/zh
Publication of CN109689028A publication Critical patent/CN109689028A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201780056037.8A 2016-07-12 2017-07-12 用于中枢神经系统递送和治疗隐球菌感染的脂质卷包封的抗真菌化合物 Pending CN109689028A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111352284.7A CN114053417A (zh) 2016-07-12 2017-07-12 用于中枢神经系统递送和治疗隐球菌感染的脂质卷包封的抗真菌化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662361351P 2016-07-12 2016-07-12
US62/361351 2016-07-12
US201762513800P 2017-06-01 2017-06-01
US62/513800 2017-06-01
PCT/US2017/041750 WO2018013711A1 (en) 2016-07-12 2017-07-12 Encochleated antifungal compounds for central nervous system delivery and treatment of cryptococcus infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202111352284.7A Division CN114053417A (zh) 2016-07-12 2017-07-12 用于中枢神经系统递送和治疗隐球菌感染的脂质卷包封的抗真菌化合物

Publications (1)

Publication Number Publication Date
CN109689028A true CN109689028A (zh) 2019-04-26

Family

ID=60952715

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202111352284.7A Pending CN114053417A (zh) 2016-07-12 2017-07-12 用于中枢神经系统递送和治疗隐球菌感染的脂质卷包封的抗真菌化合物
CN201780056037.8A Pending CN109689028A (zh) 2016-07-12 2017-07-12 用于中枢神经系统递送和治疗隐球菌感染的脂质卷包封的抗真菌化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202111352284.7A Pending CN114053417A (zh) 2016-07-12 2017-07-12 用于中枢神经系统递送和治疗隐球菌感染的脂质卷包封的抗真菌化合物

Country Status (8)

Country Link
US (3) US11123295B2 (enExample)
EP (1) EP3484447A4 (enExample)
JP (1) JP6991592B2 (enExample)
KR (2) KR20190029642A (enExample)
CN (2) CN114053417A (enExample)
AU (1) AU2017297402B2 (enExample)
CA (1) CA3027668A1 (enExample)
WO (1) WO2018013711A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114269335A (zh) * 2019-08-13 2022-04-01 马蒂纳斯生物制药纳米科技有限公司 治疗隐球菌感染的方法
WO2024152985A1 (zh) * 2023-01-20 2024-07-25 中国科学院微生物研究所 肌醇磷脂酰胺合成酶抑制剂与两性霉素b的联合用药及其用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2688397T3 (es) 2012-07-30 2018-11-02 Matinas Biopharma Nanotechnologies, Inc. Cocleatos hechos con fosfatidilserina de soja

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837254A (en) * 1996-11-14 1998-11-17 Chen; Yu Method of treating candida and cryptococcus fungal infections by administering gentian
US5925616A (en) * 1996-08-09 1999-07-20 Buckman Laboratories International, Inc. Treatment of fungal infections using a combination of an anti-fungal compound and an H-alkyl heterocyclic compound
CA2480265A1 (en) * 2002-03-26 2003-10-09 Biodelivery Sciences International, Inc. Cochleates made with purified soy phosphatidylserine
CA2504329A1 (en) * 2002-11-01 2004-05-21 Biodelivery Sciences International, Inc. Geodate delivery vehicles
WO2004092123A2 (en) * 2003-04-10 2004-10-28 Microbia, Inc. Inhibitors of fungal invasion
US20090087480A1 (en) * 2005-04-07 2009-04-02 Toyama Chemical Co., Ltd. Pharmaceutical composition and method using antifungal agent in combination

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153217A (en) 1999-01-22 2000-11-28 Biodelivery Sciences, Inc. Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents
AUPQ066399A0 (en) 1999-05-31 1999-06-24 Fujisawa Pharmaceutical Co., Ltd. Antifungal combination use
JP2003529557A (ja) 2000-01-24 2003-10-07 バイオデリバリー サイエンス インコーポレーテッド コクリエート製剤、その調製方法および生物学的関連分子投与のための用途
WO2004091578A2 (en) 2003-04-09 2004-10-28 Biodelivery Sciences International, Inc. Novel encochleation methods, cochleates and methods of use
EP2626415A3 (en) * 2004-10-25 2014-04-16 Cellerant Therapeutics, Inc. Methods of expanding myeloid cell populations and uses thereof
WO2007002886A2 (en) * 2005-06-29 2007-01-04 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic pr0tein-lip1d complexes
WO2009006311A2 (en) * 2007-06-29 2009-01-08 Wisconsin Alumni Research Foundation Structuring effect of cholesterol in peg-phospholipid micelles, drug delivery of amphotericin b, and combination antifungals
DE102008054431B3 (de) * 2008-12-09 2010-06-17 Pari Pharma Gmbh Aerosoltherapievorrichtung
WO2010091090A1 (en) 2009-02-03 2010-08-12 Biodelivery Sciences International, Inc. Cochleate compositions and methods of use
CA2834788C (en) * 2011-05-05 2020-11-17 Coordinated Program Development, Llc Cochleate compositions and methods of making and using same
ES2688397T3 (es) 2012-07-30 2018-11-02 Matinas Biopharma Nanotechnologies, Inc. Cocleatos hechos con fosfatidilserina de soja

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925616A (en) * 1996-08-09 1999-07-20 Buckman Laboratories International, Inc. Treatment of fungal infections using a combination of an anti-fungal compound and an H-alkyl heterocyclic compound
US5837254A (en) * 1996-11-14 1998-11-17 Chen; Yu Method of treating candida and cryptococcus fungal infections by administering gentian
CA2480265A1 (en) * 2002-03-26 2003-10-09 Biodelivery Sciences International, Inc. Cochleates made with purified soy phosphatidylserine
CA2504329A1 (en) * 2002-11-01 2004-05-21 Biodelivery Sciences International, Inc. Geodate delivery vehicles
WO2004092123A2 (en) * 2003-04-10 2004-10-28 Microbia, Inc. Inhibitors of fungal invasion
US20090087480A1 (en) * 2005-04-07 2009-04-02 Toyama Chemical Co., Ltd. Pharmaceutical composition and method using antifungal agent in combination

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114269335A (zh) * 2019-08-13 2022-04-01 马蒂纳斯生物制药纳米科技有限公司 治疗隐球菌感染的方法
WO2024152985A1 (zh) * 2023-01-20 2024-07-25 中国科学院微生物研究所 肌醇磷脂酰胺合成酶抑制剂与两性霉素b的联合用药及其用途

Also Published As

Publication number Publication date
KR20230003167A (ko) 2023-01-05
WO2018013711A1 (en) 2018-01-18
CA3027668A1 (en) 2018-01-18
CN114053417A (zh) 2022-02-18
KR20190029642A (ko) 2019-03-20
AU2017297402B2 (en) 2023-02-09
AU2017297402A1 (en) 2019-01-03
JP2019520407A (ja) 2019-07-18
US20240423916A1 (en) 2024-12-26
JP6991592B2 (ja) 2022-01-12
US11123295B2 (en) 2021-09-21
EP3484447A1 (en) 2019-05-22
US20210393526A1 (en) 2021-12-23
US20200121601A1 (en) 2020-04-23
EP3484447A4 (en) 2020-07-22

Similar Documents

Publication Publication Date Title
JP2958774B2 (ja) アンホテリシンｂリポソームの改良調整法
US12409227B2 (en) Cochleates made with soy phosphatidylserine
Pensel et al. Cystic echinococcosis therapy: albendazole-loaded lipid nanocapsules enhance the oral bioavailability and efficacy in experimentally infected mice
US20240423916A1 (en) Encochleated antifungal compounds for central nervous system delivery and treatment of cryptococcus infections
CN103860469A (zh) 脂质体万古霉素制剂
Chen et al. Multi-functional vesicles improve Helicobacter pylori eradication by a comprehensive strategy based on complex pathological microenvironment
US20110020428A1 (en) Gel-stabilized liposome compositions, methods for their preparation and uses thereof
Cheng et al. Berberine-loaded mannosylerythritol lipid-B nanomicelles as drug delivery carriers for the treatment of Helicobacter pylori biofilms in vivo
CN103622924A (zh) 一种多西他赛脂质体及其制备方法
Louaguenouni et al. Robust micelles formulation to improve systemic corticosteroid therapy in sepsis in multiple healthcare systems
US20220313717A1 (en) Methods of treating cryptococcus infections
EP4572770A1 (en) Antifungal agent encapsulated in a lipid nanocrystal for treating mucormycosis
CN117815398A (zh) 一种胆固醇丁基双胍偶联物在制剂中的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190426